Fundraising Fox
Scribe Therapeutics
NASDAQ: SCTXBerkeley, US · Founded 2017 · Delaware corporation · 89 employees on LinkedIn · 6 known investors
Find your way into Scribe Therapeutics
Sign up to see every warm intro you have to Scribe Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Scribe Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.
Founders & leadership
Scribe Therapeutics was founded in 2017 by Benjamin Oakes, Jennifer A. Doudna, PhD, Benjamin L. Oakes, PhD, David F. Savage, PhD, and Brett Staahl, PhD.
Board
Investors · 6
How we know: the company's own site · a16z's portfolio · the S-1 prospectus · board seat on SEC Form D · funding news · Not right? Tell us
How we know: OrbiMed's portfolio page · the company's own site · the S-1 prospectus · funding news · the VCSheet dataset · Not right? Tell us
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: Menlo Ventures's portfolio page · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: RA Capital's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$100M disclosed across 1 round · 2021
▶$100MraisedApr 2021 · 19 investors · Other TechnologyRule 506(b)
- Benjamin OakesExecutive Officer, Director
- Vijay PandeDirector
- Carl GordonDirector
- Behzad AghazadehDirector
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 4
Companies working in the same space as Scribe Therapeutics.
Frequently asked questions
- What does Scribe Therapeutics do?
- Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.
- Who founded Scribe Therapeutics?
- Scribe Therapeutics was founded by Benjamin Oakes, Jennifer A. Doudna, PhD, Benjamin L. Oakes, PhD, David F. Savage, PhD, Brett Staahl, PhD in 2017.
- Who are Scribe Therapeutics's investors?
- Scribe Therapeutics's investors include Andreessen Horowitz, OrbiMed, Avoro Capital Advisors, Menlo Ventures, RA Capital, Wellington Management.
- How much funding has Scribe Therapeutics raised?
- Scribe Therapeutics has disclosed $100M raised across 1 round.
- Where is Scribe Therapeutics headquartered?
- Scribe Therapeutics is headquartered in Berkeley, US.